Company: NDRA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001654954-25-003612
Chunk: 445

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 2
Chunk 445
---
         Weighted average common shares – basic and diluted  202,106   3,636 

The accompanying notes are an integral part of these consolidated financial statements.

 F-3 

ENDRA Life Sciences Inc.

Consolidated Statements of Stockholders’ Equity

Year Ended December 31, 2023  Series A Convertible  Series B Convertible             Total    Preferred Stock  Preferred Stock  Common stock  Additional    Accumulated  Stockholders’   Shares   Amount  Shares   Amount  Shares   Amount  Paid in Capital  Stock Payable  Deficit  Equity Balance as of December 31, 2022   141.397  $1   -  $-   1,811  $-  $89,068,332  $6,073  $(81,869,902) $7,204,504 Common stock issued for cash, net of funding costs  -   -   -   -   3,221   1   6,483,392   -   -   6,483,393 Common stock issued for warrant exercise  -   -   -   -   905   -   1,014,859   -   -   1,014,859 Warrants issued for cash, net of funding costs  -   -   -   -   -   -   20,053   -   -   20,053 Fair value of vested stock options  -   -   -   -   -   -   996,430   -   -   996,430 Stock payable towards preference dividend  -   -   -   -   -   -   840   (840)  -   - Net loss  -   -   -   -   -   -   -   -   (10,060,250)  (10,060,250)Balance as of December 31, 2023   141.397  $1   -  $-   5,937  $1